Donation

Praziquantel Donation Program

Merck KGaA’s Praziquantel Donation Program, in partnership with the World Health Organization (WHO), aims to fight schistosomiasis in Africa. Schistosomiasis is a parasitic worm disease that is the second most prevalent and devastating parasitic disease in tropical countries after malaria. Infection occurs when human skin comes into contact with fresh water contaminated by snails carrying the schistosome parasites, which migrate through the body and spread the infectious disease. It represents the 2nd most severe burden for African children after malaria, and is considered as one of the most neglected tropical diseases. The consequences of an infection are particularly serious for children, as schistosomiasis stunts growth and cognitive development and also lead to anemia. WHO reports more than 200 million infected people in Americas, Africa, the Middle East, Southeast and the Western Pacific.

Stop TB Partnership

Established in 1998 and hosted by the World Health Organization (WHO), the Stop TB Partnership aims to provide global leadership, strategy, and coordinating mechanisms. The Stop TB priorities are to expand, adapt, and improve strategies to control and eliminate TB in support of the World Health Assembly Targets set by 2005 (70% case-detection and 85% cure-rates) and the Millennium Development Goals. The mission is to ensure that every TB patient has access to TB treatment and cure, to protect vulnerable populations from TB and to reduce the social and economic toll that TB exerts on families, communities and nations.

Sikiliza Leo Project, Uganda

Johnson & Johnson, its Tibotec subsidiary and the African Medical Research Foundation help the Ugandan NGO Sikiliza Leo to provide HIV testing, counseling, treatment and care in rural Uganda. Since March 2003, HIV testing and counseling have been offered to 3,586 community members, of whom 559 have tested positive for HIV. A total of 272 persons receive Home Based Care and a first group of 20 are now receiving ARV therapy.

Sigma-Tau & AMREF: 'Uganda Project'

Sigma-Tau supports the African Medical Research Foundation (AMREF) in implementing the 'Uganda Project', a vaccination and medical training program in Northern Uganda, in the areas most affected by the civil war of the 1990s. The main aim of the project is to vaccinate more than 3,000 Ugandan children against the six most common childhood diseases (tuberculosis, diphtheria, tetanus, poliomyelitis, hepatitis B and measles). At the same time, it also aims to provide medical training for local health workers, thus furnishing both immediate and long-term support for health development.

Sanofi-aventis Sleeping Sickness Program

Sleeping sickness has reemerged in Africa as a major health threat. In 2001, sanofi-aventis committed USD 25 million over the years 2001-2006 to help the World Health Organization (WHO) to implement a strategy of adequate medicine supplies, disease surveillance and management, plus R&D for new treatments. After five years, WHO and sanofi-aventis' efforts were estimated to have saved 110,000 lives. In 2006, the company renewed its contract with the WHO and expanded it to address several additional 'most neglected diseases' (see separate entry).

Sanofi-aventis Children's Programs

Sanofi-aventis supports a number of projects in developing countries, the main purpose of which is to help improve children's health.

Rotavirus Vaccine Program

The Rotavirus Vaccine Program works to accelerate the introduction of new vaccines to treat rotavirus.

Pneumococcal Conjugate Vaccine Programs

Pneumococcal disease takes the lives of 1.6 million people each year, including approximately 800,000 children before their fifth birthday. More than 90% of these deaths occur in developing countries. Its most common serious form, pneumonia, accounts for one in every four child deaths. GlaxoSmithKline and Pfizer have developed pneumococcal conjugate vaccines which protect against this major health threat.

PMTCT: Abbott Rapid HIV Test Donation Program

Each year, approximately 800,000 babies around the world become infected with HIV during their mothers´ pregnancy, during birth or through breastfeeding.

Pfizer Diflucan Partnership

Pfizer created the Diflucan Partnership in 2000 to provide treatment for two AIDS-related fungal infections in developing countries. Since the program's inception, Pfizer has over provided USD 1.1 billion of products and its program partners distribute millions of Diflucan (fluconazole) treatments free of charge to governments and NGOs in 63 developing countries in Africa, Asia, the Caribbean and Latin America. Pfizer has also provided training and education materials to 20,000 healthcare professionals.

Pages